Drugs / IxCell hUC-MSC-S
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05697718 | Apr 2023 → Jul 2024 | ischemic stroke | Shanghai IxCell Biotechnology Co., LTD | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07197606 | Oct 2025 → Jun 2027 expected | ischemic stroke | Shanghai IxCell Biotechnology Co., LTD | Not yet recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IxCell hUC-MSC-S | “Clinical Trial of Human Umbilical Cord Mesenchymal Stem Cells (IxCell hUC-MSC-S) in the Treatment of Ischemic Stroke” NCT05697718 ↗ |
| Known as | hUC-MSCs | “The goal of this clinical trial is to evaluate the efficacy, safety, and pharmacodynamic characteristics of Human Umbilical Cord Mesenchymal Stem Cells (hUC-MSCs) in adults...” NCT07197606 ↗ |
| Action | Restore | “replacing damaged nerve cells” NCT05697718 ↗ |
| Modality | Cell therapy | “Umbilical cord-derived mesenchymal stem cells (UC-MSCs)” PMID 42208543 ↗ May 2026 |
| Route | Intravenous | “a single intravenous infusion” NCT05697718 ↗ |